Jean-François Formela, MD

Jean-François Formela is a partner and focuses on novel drug discovery approaches and therapeutics. He joined Atlas Venture in 1993 to build the U.S. life sciences franchise.

He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA), and Korro Bio. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics.

His prior investments include Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL, acquired by Merck), Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by Novartis), Exelixis (NASDAQ: EXEL), Horizon Therapeutics (NASDAQ: HZNP), NxStage (NASDAQ: NXTM, acquired by Fresenius), and Translate Bio (NASDAQ: TBIO, acquired by Sanofi).

Jean-François is a member of the Mass General Brigham Innovation Advisory Board and a former trustee of the Boston Institute of Contemporary Art. He received his MD from Paris University School of Medicine and his MBA from Columbia University.

Partner, Atlas Venture


Join our email list to receive exclusive offers

Opt In